Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression

Página do item simplificado
dc.creatorLuciana Mendes Araújo Borém
dc.creatorSergio Henrique Sousa Santos
dc.creatorDaniela Fernanda de Freitas
dc.creatorAmanda Souto Machado
dc.creatorAlanna Fernandes Paraiso
dc.creatorBruna Viana Caldas
dc.creatorJoão Felício Rodrigues Neto
dc.creatorJuliana Pinto Lima
dc.creatorAndré Luiz Senna Guimarães
dc.creatorAlfredo Mauricio Batista de Paula
dc.date.accessioned2023-11-13T22:35:49Z
dc.date.accessioned2025-09-09T00:37:33Z
dc.date.available2023-11-13T22:35:49Z
dc.date.issued2022-09-14
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1186/s43066-022-00216-w
dc.identifier.issn2090-6226
dc.identifier.urihttps://hdl.handle.net/1843/60917
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofEgyptian Liver Journal
dc.rightsAcesso Aberto
dc.subjectObesidade
dc.subjectFígado
dc.subject.otherRenin-angiotensin system
dc.subject.otherObesity
dc.subject.otherAngiotensin-(1–7)
dc.subject.otherNon-alcoholic fatty liver disease
dc.titleAngiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression
dc.typeArtigo de periódico
local.citation.epage12
local.citation.issue55
local.citation.spage1
local.citation.volume12
local.description.resumoBackground Telmisartan is a non-peptide angiotensin II receptor antagonist which acts by ACE/AngII/AT1 axis blockade (ARB). In the last years increasing evidence of its metabolic benefits pointed out this drug as the most promising ARB for nonalcoholic fatty liver disease (NAFLD) treatment. The aim of the present study was to investigate the Telmisartan effect on treating NAFLD in mice fed with a high-fat diet evaluating liver gene modulation. Twenty-four male mice were divided into four groups and fed for 60 days with a standard diet (ST), standard diet plus TEL (ST+TEL 5 mg/kg/day by gavage for 4 weeks), high-fat diet (HFD), or high-fat diet plus TEL (HFD+TEL 5 mg/kg/day by gavage for 4 weeks). Body weight, lipid profile, insulin, alanine transaminase, and aspartate aminotransferase were evaluated. Liver histology was analyzed. US imaging was performed to access liver dimension and echogenicity and also epididymal fat pad thickness. The expression of proinflammatory resistin/TRL4/MYD88 pathway was analyzed. Results The main findings showed that TEL reduced the resistin, TRL4, and Myd88 liver expression in the HFD + TEL group when compared to the obese control group (HFD). Decreased hepatic steatosis in the HFD + TEL group demonstrated by US measurements of the liver longitudinal axis and echogenicity were observed. In addition, TEL reduced epididymal adipose pad thickness, body weight, transaminases, and improved glucose tolerance test and HDL cholesterol. Conclusions We observed that Telmisartan treatment improved metabolism, decreasing NAFLD.
local.identifier.orcidhttp://orcid.org/0000-0002-7788-5447
local.publisher.countryBrasil
local.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS
local.publisher.initialsUFMG
local.url.externahttps://eglj.springeropen.com/articles/10.1186/s43066-022-00216-w#rightslink

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression.pdf
Tamanho:
1.29 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
978 B
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG